Raloxifene is indicated for the treatment of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.
When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
For this indication, competent medicine agencies globally authorize below treatments:
Oral
60 - 60 mg
From 60 To 60 mg once every day
The recommended dose is 60 mg daily by oral administration, which may be taken at any time of the day without regard to meals. Due to the nature of this disease process, raloxifene is intended for long term use.
Generally calcium and vitamin D supplements are advised in women with a low dietary intake.
No dose adjustment is necessary for the elderly.